Skip to main content

Table 2 Serum levels of SP-A, SP-D, and KL-6 at baseline, 3, and 6 months

From: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

 Baseline3 months6 months
Stable group
 SP-A (ng/mL)60.3 (42.6–76.1)53.1 (36.6–68.0) *49.2 (37.1–71.7) *
 SP-D (ng/mL)241 (177–357)194 (149–296)195 (128–263)
 KL-6 (U/mL)885 (595–1618)775 (581–1154) *738 (503–1213) *#
Progression group
 SP-A (ng/mL)56.6 (40.6–96.7)67.0 (46.8–111.8) *69.3 (42.7–117.8) *
 SP-D (ng/mL)246 (166–350)261 (180–323)224 (192–353)
 KL-6 (U/mL)901 (732–1337)1195 (653–1821)1237 (748–1570) #
  1. Data are expressed as medians (interquartile range).
  2. *: Bonferroni-corrected p < 0.05 baseline vs. 3 or 6 months. #: p < 0.05 stable group vs. progression group. SP surfactant protein; KL-6 Krebs von den Lungen-6